[Postprandial hypoglycemia].
Mori
Yutaka
Y
Department of Internal Medicine, National Hospital Organization, Utsunomiya National Hospital.
D020909:Acarbose / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D050528:Diet, Carbohydrate-Restricted; D004043:Dietary Fiber / Q000008:administration & dosage; D004377:Dumping Syndrome / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005743:Gastrectomy / Q000009:adverse effects; D018149:Glucose Intolerance / Q000150:complications* / Q000503:physiopathology; D005951:Glucose Tolerance Test; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015431:Weight Loss
D003510:Cyclohexanes; D004043:Dietary Fiber; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D000077715:Nateglinide; D010649:Phenylalanine; D020909:Acarbose